Angiogenesis is a process that involves endothelial cell proliferation, migration, invasion, and tube formation, and inhibition of these processes has implications for angiogenesis-mediated disorders. The purpose of this study was to evaluate the antiangiogenic efficacy of YC-1 [3-(5Ј-hydroxymethyl-2Ј-furyl)-1-benzyl indazole] in well characterized in vitro and in vivo systems. YC-1 inhibited the ability of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in a dose-dependent manner to induce proliferation, migration, and tube formation in human umbilical vascular endothelial cells; these outcomes were evaluated using [ 3 H]thymidine incorporation, transwell chamber, and Matrigel-coated slide assays, respectively. YC-1 inhibited VEGF-and bFGF-induced p42/p44 mitogen-activated protein kinase and Akt phosphorylation as well as protein kinase C␣ translocation using Western blot analysis. The effect of YC-1 on angiogenesis in vivo was evaluated using the mouse Matrigel implant model. YC-1 administered orally in doses of 1 to 100 mg/kg/day inhibited VEGF-and bFGF-induced neovascularization in a dose-dependent manner over 7 days. These results indicate that YC-1 has antiangiogenic activity at very low doses. Moreover, in transplantable murine tumor models, YC-1 administered orally displayed a high degree of antitumor activity (treatment-to-control life span ratio Ͼ 175%) without cytotoxicity. YC-1 may be useful for treating angiogenesis-dependent human diseases such as cancer.
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Angiogenesis is the formation of new blood vessels from preexisting endothelial vasculature (Folkman et al., 1971) . Physiologically, angiogenesis plays a crucial role in embryonic development, placental implantation, and wound healing. In contrast, the same process also supports pathological conditions such as solid tumor growth, diabetic retinopathy, psoriasis, and rheumatoid arthritis. Complex and diverse cellular actions such as extracellular matrix degradation, proliferation and migration of endothelial cells, and morphological differentiation of endothelial cells to form tubes have all been implicated in angiogenesis (Bussolino et al., 1997) .
Although all of these processes are regulated under normal conditions, abnormal vascularization is clearly implicated in malignant tumor growth and metastasis. The extreme growth of tumors to volumes larger than a few cubic millimeters requires continuous recruitment of new blood vessels (Folkman, 1990) . These newly synthesized blood vessels also provide a route for cancer cells to enter the systemic circulation and spread to distant organs (Fidler and Ellis, 1994) . A growing number of angiogenic factors have been recognized as contributors to regulation of tumor angiogenesis. When a balance between angiogenic and angiostatic factors is disrupted, uncontrolled angiogenic factors such as growth factors, cytokines, lipid metabolites, and cryptic fragments of hemostatic proteins can be released from tumor cells. Among these angiogenesis-related factors are vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) (Klein et al., 1997; Ferrara, 2001) . These factors are produced by many pathologic (tumor) and normal cells, and they stimulate endothelial cell proliferation, sprouting, migration, and morphogenesis. They act via receptor tyrosine kinases and influence normal and abnormal angiogenesis (Friesel and Maciag, 1999; Cross and Claesson-Welsh, 2001) .
YC-1 is a novel NO-independent type of soluble guanylyl cyclase (sGC) activator that mimics many of the known functions of NO and NO donors. YC-1 was discovered in Teng's laboratory (Ko et al., 1994) . YC-1 and NO synergistically activate sGC in vitro, and YC-1 potentiates the effects of exogenous and endogenous carbon monoxide on sGC (Friebe et al., 1996) . YC-1 at a high concentration level (e.g., Ͼ30 M) induces these cellular and physiological functions via cGMP-dependent or independent pathways (Wang et al., 2002; Chien et al., 2003; Pan et al., 2004) . However, we have not found published studies reporting an inhibitory effect of YC-1 on endothelial cells at a very low concentration. In this study, we determined that low levels of YC-1 suppressed endothelial cell proliferation, migration, and tube formation in vitro and inhibited VEGF-and bFGF-induced angiogenic signaling pathways. YC-1 also markedly inhibited neovascularization induced by VEGF and bFGF in vivo in the Matrigel plug implantation model. Finally, YC-1 prolonged the lifespan of tumor-treated animals in an antitumor activity experiment without producing any apparent cytotoxicity. Taken together, these results suggest that YC-1 may inhibit tumor activity via the antiangiogenic properties demonstrated at a low level of exposure.
Materials and Methods
Cell Culture. Human umbilical vein endothelial cells (HUVECs) were obtained from human umbilical cord veins with collagenase, isolated according to protocols from Jaffe et al. (1973) , and cultured in 75-cm 2 plastic flasks in M199 medium containing 20% fetal bovine serum (FBS) and 15 g/ml endothelial cell growth supplements. Confirmation of cell identity as endothelial cells was provided by detection of CD31 (PECAM-1) by immunostaining. The human lung cancer cell line A549 was cultured in Dulbecco's modified Eagle's medium containing 10% inactivated FBS. Cells were incubated at 37°C in a humidified atmosphere of 5% CO 2 in air. Medium was changed every 2 days, and cells were passaged after treatment with a solution of 0.05% trypsin/0.02% EDTA. Experiments were conducted on HUVECs that had gone through two to five passages.
[ 3 H]Thymidine Incorporation Assay. Confluent HUVECs were trypsinized, suspended in M199 medium supplemented with 20% FBS, and seeded at 1.0 ϫ 10 4 cells per well into 96-well plates. After 24 h, the cells were washed twice with phosphate-buffered saline (PBS) and starved with 2% FBS-M199 medium for 24 h. The cells were then incubated with or without indicated reagents and growth factors (e.g., VEGF and bFGF at 10 ng/ml) for 24 h and harvested. Before the harvest, cells were incubated with [ 3 H]thymidine (2 Ci/ml) for 4 h. Cells were harvested with Filter-Mate (PerkinElmer Life and Analytical Sciences, Boston, MA), and incorporated radioactivity was determined.
Migration Assay. Chemotactic migration of HUVECs was measured with a transwell migration apparatus as described previously by Pan et al. (2003) . Cell migration was assayed in 24-well, 6.5-mminternal diameter chamber cluster plates (8-m pore size; Costar, Cambridge, MA). Briefly, HUVECs (1 ϫ 10 5 cells/well) were suspended in 200 l of serum-free M199 medium with 0.1% bovine serum albumin and loaded into the upper chamber of a transwell cluster plate coated with 0.1 mg/ml gelatin. VEGF or bFGF was diluted to 10 ng/ml in 0.6 ml of M199/0.1% bovine serum albumin and added to the lower wells of the chamber. YC-1 (3-30 M) was added at the indicated concentration 1 h before the assay. The chambers were incubated for 24 h at 37°C in an atmosphere of 95% air and 5% CO 2 . At the end of incubation, cells were fixed and stained with hematoxylin. Nonmigrated cells on top of the filters were wiped off, filters were mounted, and migrated cells attached to the bottom of the filter were counted in six randomly chosen (ϫ400) high-power fields. Cell migration was calculated as the difference between the number of migrated cells in the YC-1-treated samples and the number of migrated cells in the control samples.
Tube Formation Assay. HUVECs (2 ϫ 10 5 cells) were seeded on a layer of polymerized Matrigel with or without YC-1 (3-30 M) and VEGF or bFGF (10 ng/ml) in a chamber slide (Nalge Nunc International, Naperville, IL). Matrigel cultures were incubated at 37°C. After 24 h, cell morphology was evaluated using a phase-contrast microscope, and cells were photographed.
PKC Fractionation in HUVECs. Cells were homogenized in 0.2 ml of buffer A containing 20 mM HEPES (pH 7.5), 0.33 M sucrose, 2 mM EGTA, 2 mM EDTA, 5 mM dithiothreitol, 20 mM sodium fluoride, 0.1 mM sodium orthovanadate, 20 g/ml leupeptin, 10 g/ml aprotinin, and 0.2 mM phenylmethyl sulfonyl fluoride. The cytosolic fraction (supernatant) was separated by centrifugation at 100,000g for 60 min. The pellet was resuspended in homogenization buffer A without sucrose but with 0.1% Triton X-100, followed by centrifugation and collection of the particulate fraction (supernatant). The samples were processed for SDS-polyacrylamide gel electrophoresis and immunoelectrophoresis.
Western Blotting. After exposure of cells to indicated agents over specified time courses, cells were washed twice with ice-cold PBS, and reaction was terminated by addition of 100 l of ice-cold lysis buffer (10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EGTA, 0.5 mM phenylmethyl sulfonyl fluoride, 10 g/ml aprotinin, 10 g/ml leupeptin, and 1% Triton X-100). Protein (60 g/lane) was separated on 7.5 to 12% SDS-polyacrylamide gel electrophoresis. The nitrocellulose membrane was immunoreacted with the primary antibody to ERK1/2, phosphorylated-ERK1/2 (BD Biosciences, San Jose, CA), Akt, phosphorylated-Akt, ␣-tubulin (Santa Cruz Biotechnology, Inc., Santa Cruz, CA), and PKC␣ (Serotec, Oxford, UK) for overnight incubation at 4°C. After four washings with PBS/0.1% Tween 20, the secondary antibody (diluted 1:2000) was applied to the membranes for 1 h at room temperature. Antibody-reactive bands were detected with an enhanced chemiluminescence kit (ECL; Amersham Biosciences UK, Ltd., Little Chalfont, Buckinghamshire, UK).
In Vivo Matrigel Plug Assay. Nude mice (6 weeks of age) were given subcutaneous injections of 500 l of Matrigel (BD Biosciences) at 4°C with growth factor (150 ng/ml VEGF or bFGF). After injection, the Matrigel rapidly formed a plug. YC-1 (1-100 mg/kg/day) was given orally starting on day 1. After 7 days, the skin of the mouse was easily pulled back to expose the Matrigel plug, which remained intact. After quantitative differences were noted and photographed, hemoglobin was measured as an indication of blood vessel formation, using the Drabkin method (Drabkin reagent kit 525; Sigma-Aldrich, St. Louis, MO). The concentration of hemoglobin was calculated from a known amount of hemoglobin assayed in parallel.
In Vivo Antitumor Activity Assay. A549 (1 ϫ 10 7 ) cells in a volume of 100 l were transplanted through the chest wall into the left pleural space of nude mice using a 26-gauge needle on day 0; a dose of 10 mg/kg/day YC-1 was given orally starting on day 1. Antitumor activity was assessed as the ratio of median survival time (MST) in the treatment group (T) to MST in the control group (C), and the results are shown as T/C: life span T/C (%) ϭ (MST of drug-treated group/MST of control group) ϫ 100. Long-term survivors were recorded until each animal died.
Cytotoxicity Assay. The cytotoxicity assay was carried out using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay method. MTT (Sigma-Aldrich) was dissolved in PBS at a concentration of 5 mg/ml and sterilized by filtration (Millipore Corporation, Billerica, MA). From this stock solution, 10 l/100 l medium was added to each well, and plates were gently shaken and 36 incubated at 37°C for 2 h. After the incubation period, cells were lysed with dimethyl sulfoxide and quantified at OD 550 with an enzyme-linked immunosorbent assay reader.
Data Analysis and Statistics. Data are presented as mean Ϯ S.E.M. or as percentage of control. Statistical comparisons between groups were performed using the Student's t test. P Ͻ 0.05 was considered statistically significant.
Results
Effect of YC-1 on VEGF-and bFGF-Induced Cell Proliferation of HUVECs. The ability of YC-1 to affect the mitogen activity of VEGF and bFGF was assessed in a [ 3 H]thymidine incorporation assay. YC-1 (0.01-1 M) inhibited, in a dose-dependent manner, cell growth induced by 10 ng/ml VEGF and bFGF (IC 50 values of 1.4 ϫ 10 Ϫ7 and 9.0 ϫ 10 Ϫ8 M, respectively) (Fig. 1A) . YC-1 was also tested for its capacity to affect HUVEC proliferation stimulated by 20% FBS to assess the specificity of this effect. Under the same experimental conditions, YC-1 inhibited the mitogenic activity stimulated by VEGF and bFGF but not by FBS in the same concentration range (data not shown).
YC-1 may inhibit cell proliferation through effects on a cyclic GMP-dependent pathway or potentate a nitric oxidemediated pathway in endothelial cells. Accordingly, we investigated the effect of ODQ (a sGC inhibitor, 3 and 10 M), 100 M dibutyl cGMP (a cyclic GMP analog), and 1 mM L-NAME (a nitric oxide synthase inhibitor) on YC-1 antiproliferative activity. ODQ and L-NAME did not reverse YC-1-induced antiproliferation in HUVECs (Fig. 1, B and C) . Dibutyl cGMP completely inhibited YC-1 induced cell proliferation but only in high concentrations. Taken together, these results demonstrate that YC-1 inhibits VEGF-and bFGF-induced HUVECs proliferation and that this inhibition does not involve effects on cyclic GMP-dependent or nitric oxide-mediated pathways.
Effect of YC-1 on VEGF-and bFGF-Induced Cell Migration and Tube Formation of HUVECs. Next, we used well established assays to assess the potential regulatory role of YC-1 on cell migration and differentiation. YC-1 (3-30 M) significantly inhibited, in a dose-dependent manner, VEGFand bFGF-induced cell migration in a transwell assay ( Fig.  2A) . However, HUVECs treated with 10 ng/ml VEGF and bFGF reorganized and subsequently formed capillary-like structures (Fig. 2B) . YC-1 (3-30 M) caused a concentrationdependent blockage of the capillary tubes and did not inhibit cell viability (MTT assay). These results demonstrate that YC-1 has the ability to block VEGF-and bFGF-induced in vitro angiogenesis.
Effect of YC-1 on VEGF-and bFGF-Induced ERK1/2 and PI3-K Activation in HUVECs. As mentioned above, the activation of both ERK1/2 and PI3-K pathways is required for the proliferative and migratory effects of VEGF and bFGF on endothelial cells (Cross and Claesson-Welsh, 2001 ). Therefore, we evaluated the possibility that the inhibitory effect of YC-1 might be mediated through its ability to interfere with VEGF-and bFGF-induced activation of these intracellular pathways. To determine whether YC-1 could modulate these active signaling pathways that are involved in cell functions, HUVECs were incubated with increasing amounts of YC-1 in vitro and analyzed for changes in activated Akt and ERK1/2. First, we assessed the effect of YC-1 (1 and 10 M) on ERK1/2 phosphorylation (Fig. 3A) . VEGFand bFGF-induced ERK1/2 phosphorylation (10 ng/ml) was strongly inhibited by YC-1 in a concentration-dependent manner. Densitometric analysis indicated that VEGF-and bFGF-induced ERK1/2 phosphorylation was reduced by 20 to 40% in the presence of 1 M YC-1 and by 50 to 60% in the presence of 10 M YC-1 (Fig. 3B) . Akt is a protein kinase recruited to the membrane and activated by phosphorylation Fig. 1 . Effect of YC-1 on VEGF-and bFGF-induced cell proliferation. A, effect of YC-1 (0.01-1 M) on growth factor (10 ng/ml VEGF or bFGF) HUVEC growth was examined using [ 3 H]thymidine incorporation to assess proliferation. B and C, cells were treated with or without YC-1 (1 M) in the absence or presence of the indicated agents, and growth factors were added for 24 h. After the incubation period, the cell proliferation was assayed using [ 3 H]thymidine incorporation assay. Data represent the mean Ϯ S.E.M. of six independent experiments (each performed in triplicate). ϩ, P Ͻ 0.001 versus basal group; ‫,ء‬ P Ͻ 0.05; ‫,ءء‬ P Ͻ 0.01; ‫,ءءء‬ P Ͻ 0.001 versus control group.
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at ASPET Journals on October 25, 2017 jpet.aspetjournals.org Downloaded from as a direct consequence of PI3 kinase activity (Cantley, 2002) . We next evaluated Akt phosphorylation levels to test whether YC-1 is also capable of inhibiting angiogenic growth factor-induced PI3-K activation. As shown in Fig. 3C , YC-1 (10 and 30 M) significantly suppressed the phosphorylation of Akt in a concentration-dependent manner. Total Akt expression was not affected by YC-1 treatment. The ratio between phosphorylated Akt and total Akt was quantified for each of the points in this experiment, and the results are shown in Fig. 3D . These data suggest that YC-1 is able to block VEGF-and bFGF-induced ERK1/2 and Akt signaling pathways in endothelial cells.
Effect of YC-1 on VEGF-and bFGF-Induced PKC␣ Activation in HUVECs. In the previous study, YC-1 significantly inhibited VEGF-and bFGF-induced HUVEC proliferation. However, VEGF and bFGF seemto exert their mitogenic effects through activation of a PKC␣-dependent pathway in human endothelial cells (Kent et al., 1995; Wellner et al., 1999) . We next evaluated whether YC-1 reduction in angiogenic activity is associated with reduced PKC␣ activity. Cells were treated with YC-1 (0.1-10 M) for 1 h followed by 10 ng/ml VEGF and bFGF for 30 min and 2 h, respectively. As shown in Fig. 4 , YC-1 significantly suppressed VEGF-and bFGF-induced PKC␣ translocation from cytosol to membrane in a concentration-dependent manner. These data suggest that YC-1 is able to block VEGF-and bFGF-induced PKC␣ signaling pathways in endothelial cells.
Effect of YC-1 on Neovascular Formation in Vivo. To determine whether YC-1 is capable of blocking VEGF-and bFGF-induced angiogenesis in vivo, we used an experimental model in which angiogenesis is induced by factors embedded in a pellet of Matrigel, which was injected subcutaneously in mice; the degree of vascularization was evaluated after 7 days. VEGF and bFGF (150 ng/ml) significantly induced angiogenic responses compared with Matrigel alone (Fig. 5, A  and B) , and YC-1 (1-100 mg/kg/day) significantly inhibited the angiogenic response in a dose-dependent manner. Microscopic examination showed that the addition of VEGF and bFGF to the Matrigel induced cellularity and the formation of cords, tubules, and several blood-filled channels containing red blood cells. In contrast, Matrigel pellets without angiogenic stimuli had only a few infiltrating, single, elongated cells. VEGF-and bFGF-induced angiogenesis was significantly reduced in mice treated with VEGF or bFGF plus YC-1 in a dose-dependent manner. Quantification of angiogenesis by hemoglobin content showed that the addition of VEGF or bFGF to the Matrigel could induce an increased angiogenic response compared with the basal group (Matrigel alone) (Fig. 5C) . However, YC-1 also inhibits the VEGF-and bFGFinduced hemoglobin content in a dose-dependent manner. These results clearly indicate that YC-1 is a potent antiangiogenic molecule in vivo.
Effect of YC-1 on Antitumor Activity in Vivo. Antitumor activity of YC-1 (10 mg/kg/day) was investigated in nude mice starting on 1 day after implantation of an A549 tumor cell line. YC-1 showed a broad spectrum and high degree of in vivo antitumor activity (Fig. 6) . The average life span was prolonged by 180%; five of the seven mice were long-term survivors (Fig. 6) ; no cytotoxicity was produced (MTT assay in cultured cancer cells; data not shown). The results indicated that YC-1 antitumor activity in the transplantable murine tumor models was due to antiangiogenic activity.
Discussion
Angiogenesis, the process of blood-vessel growth, is important during both normal development and tumor growth and metastasis. The inhibition of angiogenesis controls the expansion and metastasis of these tumors (Hanahan and Folkman, 1996) . In the present study, we demonstrated that YC-1, an activator of soluble guanylyl cyclase (Ko et al., 1994) , has antiangiogenic properties in vitro and in vivo that can suppress tumor growth. In an in vitro model system, we demonstrated that YC-1 markedly and dose dependently inhibited VEGF-and bFGF-induced endothelial cell proliferation, migration, and tube formation. VEGF and bFGF are major angiogenic factors associated with induction and maintenance of the neovasculature in tumors (Dow and DeVere, 2000; Karkkainen and Petrova, 2000) . Half-maximal inhibition was Ͻ3 M. However, under the same experimental conditions, YC-1 inhibition of the specific endothelial cell Fig. 2 . Effect of YC-1 on VEGF-and bFGF-induced cell migration and tube formation. A, cells were allowed to migrate for 24 h with indicated concentration of YC-1 and 10 ng/ml growth factor (VEGF or bFGF) in the lower chamber to stimulate chemotaxis. Data are means of three independent experiments performed in triplicate. ϩ, P Ͻ 0.001 versus basal group; ‫,ء‬ P Ͻ 0.05; ‫,ءءء‬ P Ͻ 0.001 versus control group. B, endothelial cell cord formation assays in which HUVECs in M199 medium are grown on Matrigel for 24 h in the presence or absence of indicated concentration of YC-1. To better visualize cord formation and identify the cell, viability was assayed using the MTT assay method as described under Materials and Methods. response to VEGF and bFGF was much stronger than inhibition of normal cell growth of endothelial cells. Previous studies demonstrated that YC-1 activates sGC through an NO-independent pathway (Ko et al., 1994; Yu et al., 1995) or through reducing the activity of phosphodiesterase (Friebe et al., 1998; Galle et al., 1999; Koglin et al., 2002) and that most of the actions of YC-1 are cGMP mediated. On the other hand, YC-1 can enhance the activation of sGC by NO or NO donors (Friebe et al., 1998; Rothermund et al., 2000; Friebe and Koesling, 2003) . However, our experiments demonstrated that ODQ (an sGC inhibitor) and L-NAME (a nitric oxide synthase inhibitor) did not reverse YC-1-induced antiproliferation in HUVECs. Therefore, we suggest that YC-1 inhibits VEGF-and bFGF-induced endothelial cells functions by a mechanism that is neither cGMP-dependent nor NOmediated.
In preliminarily studies, we demonstrated that treatment with high concentrations (Ͼ50 M) of YC-1 results in growth inhibition of hepatocellular carcinoma cells (HA22T) (Wang et al., 2005) or apoptosis of prostate cancer cells (PC-3) and leukemia cancer cells (HL-60 and CCRF-CEM) in culture (data not shown). Thus, the growth-inhibitory action of YC-1 at low concentration is considered to be a more specific effect on endothelial cells that are stimulated by angiogenic growth factors. Therefore, YC-1 may possess novel molecular properties that interfere with common angiogenic signaling path- As noted above, the activation of ERK1/2, PI3-K and PKC␣ pathways are required for the proliferative and migratory effects of VEGF and bFGF on endothelial cells (Cross and Claesson-Welsh, 2001 ). However, YC-1 significantly inhibits angiogenic factor-induced ERK1/2 and Akt activities as well as PKC␣ translocation from cytosol to membrane compartments in a concentration-dependent manner. Furthermore, the previous study demonstrates possible molecular mechanisms by which YC-1, at concentrations between 5 and 50 M, inhibits FBS-induced proliferation of human vascular endothelial cells in vitro (Hsu et al., 2003) . It is possible that the effect is mediated through induction of a cyclin-dependent kinase inhibitor, p21 or p27, but YC-1 did not induce any significant changes in cyclins or CDKs. However, in this study, our data show that YC-1 (0.01-1 M) did not affect HUVEC proliferation stimulated by FBS. Under the same experimental conditions, YC-1 inhibited the mitogenic activity of VEGF and bFGF, but not FBS in the same concentration range. Taken together, the data suggest that YC-1 is most likely to inhibit cell proliferation of HUVEC through VEGF-and bFGF-mediated signaling, including ERK1/2, Akt, and PKC pathways that are requisite for the angiogenic activities of VEGF and bFGF in endothelial cells.
Data from the in vivo Matrigel plug implantation animal model indicated that YC-1 markedly inhibited angiogenic growth factor-induced new vessel formation in a dose-dependent manner. Considering that angiogenesis is essential for tumor growth, the antitumor activity of YC-1 may be related to its antiangiogenic activities. Subsequently, we used the high angiogenic tumor A549, a nonsmall cell lung cancer, to assess YC-1 antitumor activity. We monitored body weights of mice every three dramatically loss from 20 g to 12 to 13 g. The results showed that YC-1 prolonged animal survival rate (Ͼ180%) after tumor cell implantation without producing cytotoxicity. However, Chun et al. (2001) and Yeo et al. (2003) demonstrated that YC-1 is an inhibitor of HIF-1␣, which halts tumor growth (by blocking tumor angiogenesis) and tumor adaptation to hypoxia. YC-1 (Ն5 ϫ 10 Ϫ6 M) sup- Downloaded from pressed HIF-1␣ protein level and expression of several HIF-1␣-regulated genes (VEGF, aldolase A, and enolase 1) in cancer cells under hypoxic conditions. YC-1 in our study showed efficacy in endothelial cells by inhibiting VEGF-and bFGF-induced angiogenic functions, such as proliferation (IC 50 Ͻ 1 ϫ 10 Ϫ7 M), migration, and differentiation (both IC 50 Ͻ 3 ϫ 10 Ϫ6 M), more than it inhibited the expression of HIF-1␣-regulated genes in cancer cells (ratio of 2-to 20-fold greater inhibition). Previous studies demonstrated that intraperitoneal injection of YC-1 (30 mg/kg) abrogates tumor growth and is associated with the suppression of tumor angiogenesis in animal models (Yeo et al., 2003) . Furthermore, we showed that oral administration of YC-1 (ID 50 ϭ 3 mg/kg) inhibited VEGF-and bFGF-induced new vessel formation in the Matrigel plug implantation model. These antiangiogenic activities of YC-1 in vivo may be explained by their direct inhibition of angiogenic factor-induced cell proliferation, migration, and differentiation in endothelial cells. Taken together, we believe that YC-1 is worth investigating further for clinical applications in cancer therapy.
In conclusion, our results demonstrated that YC-1 inhibited angiogenic responses in vitro and in vivo by blocking angiogenic factor signaling pathways, such as ones involving ERK1/2, Akt, and PKC. Inhibition of tumor activity by YC-1 is related to its antiangiogenic activity, which correlates with blockage of VEGF-and bFGF-induced endothelial cell prolif- eration, migration, and tube formation. Taken together, our results suggest that YC-1 is a potent angiogenesis inhibitor with the potential to become a useful agent in the treatment of human cancer and other angiogenesis-dependent diseases.
